Skip to Content
Morningstar

BioNTech SE ADR BNTX Stock Quote

Morningstar Rating
| Rating as of

Morningstar‘s Stock Analysis BNTX

Valuation
Currency in USD
Is it the right time to buy or sell?
Find out with Morningstar Investor
Is it the right time to buy or sell?
Find out with Morningstar Investor

1-Star Price

INVESTOR

5-Star Price

INVESTOR

Economic Moat

INVESTOR

Capital Allocation

INVESTOR

BioNTech's mRNA Technology Supports a Solid Oncology Pipeline Behind its COVID-19 Vaccine

Karen Andersen, CFA Sector Strategist

Business Strategy and Outlook

| Karen Andersen, CFA |

BioNTech, founded in 2008 in Germany, has become a key player in the development of personalized mRNA cancer treatments. The emerging biotech's first commercial vaccine, for COVID-19, received its first authorization in December 2020, and its early stage pipeline and mRNA technology platforms have caught the eye of several large pharmaceutical companies, resulting in collaborations and partnerships.

Unlock Our Full Analysis With Morningstar Investor

Key Statistics BNTX

More

Company Profile BNTX

Business Description

BioNTech is a Germany-based biotechnology company that focuses on developing cancer therapeutics, including individualized immunotherapy, as well as vaccines for infectious diseases, including COVID-19. The company's oncology pipeline contains several classes of drugs, including mRNA-based drugs to encode antigens, neoantigens, cytokines, and antibodies; cell therapies; bispecific antibodies; and small-molecule immunomodulators. BioNTech is partnered with several large pharmaceutical companies, including Roche, Eli Lilly, Pfizer, Sanofi, and Genmab. Comirnaty (COVID-19 vaccine) is its first commercialized product.

Contact
An der Goldgrube 12
Mainz, RP, D-55131, Germany
T +49 613190840
Sector Healthcare
Industry Biotechnology
Most Recent Earnings Jun 30, 2022
Fiscal Year End Dec 31, 2022
Employees 3,082

Related News BNTX

Market Update

Markets Brief: Stocks on a 4-Week Winning Streak

Inflation Reduction Act lifts clean energy; Fed minutes ahead.
Katherine Lynch
Commentary

Moderna Stock vs. Pfizer Stock: Which Is the Better Buy Now?

Both companies have been leaders in the fight against the coronavirus, but only one of their stocks is undervalued today.
Susan Dziubinski
Market Update

Markets Brief: What the June Jobs Report Could Tell Us

Retailers Bed Bath & Beyond and Kohl's shares plunge, Trip.com, BioNTech rally.
Tom Lauricella
Market Update

Markets Brief: Dodging the Bear, for Now at Least

Stocks stage a comeback to avoid falling into bear territory as TreeHouse Foods, BioNTech rally.
Tom Lauricella
Market Update

Markets Brief: Will the Volatility Continue?

Latest CPI report is on deck. Devon Energy and Occidental rally. Lyft shares plunge.
Jakir Hossain
Market Update

Markets Review/Preview: All Eyes on the Jobs Report

More strong readings on the labor market are expected as the Fed is seen moving higher, faster on rates.
Jakir Hossain
Market Update

Markets Review/Preview: Yields March Higher, Oil Slides

Chinese ADRs bounce back, Nvidia and Moderna rise, and energy stocks slump.
Jakir Hossain
Stock Strategist Industry Reports

Will Vaccine Manufacturers' Windfalls Continue Beyond 2022?

We think the COVID-19 treatment market will have more longevity.
Karen Andersen
Investing Specialists

Weekly Wrap: Undervalued Stocks for 2022, Outlook for the Market and Economy, and Your 2022 Financial Calendars

And also Tesla.
Morningstar.com
Stock Analyst Update

Fair Value Increases for Pfizer, BioNTech, and Moderna

Increased contracts for COVID-related products are just part of the reason for the upgrades.
Damien Conover
Fund Spy

The Year in U.S. Stock Funds

Value is back.
Eric Schultz
Market Update

The Best Stocks of 2021 in Morningstar’s Coverage List

Moderna and BioNTech were among a top performers list dominated by tech, energy, and consumer names.
Jakir Hossain
Stock Analyst Update

Encouraging Lab Data From Pfizer/BioNTech on Omicron

We're maintaining our fair value estimates for mRNA vaccine firms.
Karen Andersen
Stock Analyst Update

Omicron Variant Could Require Its Own Vaccine

What does this mean for leading vaccine makers Pfizer, BioNTech, and Moderna?
Karen Andersen
Fund Spy

Manager Question of the Month: How Do Managers Approach Boom-or-Bust Biotech Stocks?

Benchmark rebuild in June put pressure on some small-cap managers.
Drew Carter
Market Update

Big Biotech Shares Take a Wild Ride

As the post-pandemic pharma landscape takes shape, Moderna and BioNTech slide, Pfizer rallies.
Jakir Hossain
Stock Analyst Update

Maintaining Our Vaccine Forecast

We're not making any changes to our fair value estimates for Moderna, BioNTech, or Pfizer, and we continue to see no-moat Moderna and BioNTech as significantly overvalued at recent prices.
Karen Andersen
Stock Strategist Industry Reports

COVID-19 Vaccine Efficacy Solid Even as Delta Extends Pandemic

Hopes for eradication fade, further highlighting the benefits of vaccination and boosters.
Karen Andersen
Investing Specialists

Weekly Wrap: Buffett Buys, Falling Fund Fees, and Retirement Tips

We recap the week on Morningstar.com and note the most popular stocks, funds, and exchange-traded funds.
Morningstar.com
Stock Analyst Update

FDA Gives Full Approval to Pfizer COVID-19 Vaccine

The mRNA technology that formed the basis of the vaccine provides support to Pfizer's established wide moat and also contributes to BioNTech's positive moat trend.
Karen Andersen